Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term estrogen receptor. Found 10 abstracts

Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. 2007 Jan;31(1):121-8.
Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annual Review of Pathology-Mechanisms of Disease. 2007 Jan;2:57-85.
Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007 Jan;72(1):7-25.
Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, Daly M, Winchester DJ, Garber J, Weber BL, Domchek S, Nathanson KL. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clinical Breast Cancer. 2007 Jun;7(8):627-33.
Schor AP, Carvalho FM, Kemp C, Silva I, Russo J. S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncology reports. 2006 Jan;15(1):3-6.
Gorla SR, Hou N, Acharya S, Rademaker A, Khan S, Staradub V, Morrow M. A predictive model for the development of hormone-responsive breast cancer. Annals of Surgical Oncology. 2005 Jan;12(1):48-56.
Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast. 2005 Dec;14(6):624-30.
Nunez M, Ludes-Meyers J, Abba M, Kil H, Abbey N, Page R, Sahin A, Klein-Szanto A, Aldaz C. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Research and Treatment. 2005 Jan;89(2):99-105.
Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2004 Apr;286(4):L694-L700.
Russo J, Russo IH. Cellular basis of breast cancer susceptibility. Oncology Research. 1999 Jan;11(4):169-78.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term estrogen receptor

estrogen receptor breast cancer tamoxifen randomized-trial SURGICAL ADJUVANT BREAST TUMOR CHARACTERISTICS TUMOR-SUPPRESSOR GENE raloxifene GERMLINE MUTATIONS postmenopausal women CARRIERS THERAPY 474 TAMOXIFEN ICI 46 tuberin pathology 474 tamoxifen ici 46 CLEAR-CELL-CARCINOMA cell SMOOTH-MUSCLE advanced breast-cancer proliferation transformation FRA16D progesterone-receptor status allelotype GYNECOLOGIC-ONCOLOGY-GROUP antihormone resistance WWOX chemoprevention epithelial-cells androgen hormone-sensitive cancers carcinogens FAMILIES prognostic-significance MAMMARY-CARCINOMA MODEL RISK familial OVARIAN-CANCER REPRODUCTIVE-TRACT lobules SUSCEPTIBILITY GENE WOMEN genetics development epidemiologic characteristics receptor cancer risk WNT FACTOR-I EPIDERMAL-GROWTH-FACTOR iowa womens health genes AROMATASE INHIBITOR LETROZOLE carcinoma in-situ ashkenazi jewish mutation mouse models S100P BOWEL PROJECT P-1 TUBEROUS SCLEROSIS COMPLEX aromatase inhibitors athymic mice BRCA2 line FEMALE progesterone receptor replacement therapy 4-hydroxyandrostenedione defined medium growth risk hamartin endocrine therapy risk model region DELETIONS WELL-DIFFERENTIATED CARCINOMA prognostic-factors rat uterus IDENTIFICATION KeyWords Plus: 16q POPULATION apoptosis cancer gene expression tuberous sclerosis complex breast proliferative lesions mammary epithelial-cells family breast calcium-binding protein tumor suppressor calcium regulation RENAL ANGIOMYOLIPOMA biomarkers serous deletion pathogenesis mitogen-activated protein kinase mutation PAPILLARY SEROUS CARCINOMA tumor-suppressor human breast epithelial cell MCF-10F antihormonal therapy FAMILY REGISTRY map ANTI-TUMOUR AGENT RETROPERITONEAL HEMORRHAGE risk-factors LONG-TERM PTEN SURVIVAL estrogen-receptor TAMOXIFEN TSC1 GENE PREGNANCY SECONDARY PRODUCT FIRST-LINE positive cancers estrogen-receptor-alpha endometrioid Ki67 PULMONARY LYMPHANGIOLEIOMYOMATOSIS carcinogenesis RANDOMIZED-TRIAL molecular genetics estrogen-receptor-beta lymphangioleiomyomatosis POSTMENOPAUSAL WOMEN FREQUENCY identification chemical SIGNALING PATHWAY alcohol-consumption fragile site fra16d biopsies tumor-growth ESTROGEN-RECEPTOR STATUS SPONTANEOUS RUPTURE ESTROGEN-RECEPTOR-ALPHA IMMUNOHISTOCHEMICAL MARKERS
Last updated on Thursday, June 04, 2020